

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | — | — | 2 | 1 | 3 |
| Recurrence | D012008 | — | — | — | — | — | 1 | — | 1 |
| Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 2 | — | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 1 | — | — | — | 2 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 1 | — | — | — | 2 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 1 | 1 | — | — | — | 2 |
| Visceral leishmaniasis | D007898 | — | B55.0 | — | 1 | — | — | — | 1 |
| Leishmaniasis | D007896 | EFO_0005044 | B55 | — | 1 | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 1 | — | — | — | 1 | 2 |
| Drug common name | Sitamaquine |
| INN | sitamaquine |
| Description | Sitamaquine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCCCCCNc1cc(OC)cc2c(C)ccnc12 |
| PDB | — |
| CAS-ID | 5330-29-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL57004 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 5AIJ4TGC6B (ChemIDplus, GSRS) |
